Sangamo Announces Alignment with FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
SGMO to Seek Accelerated Approval for Fabry Gene Therapy
The Canadian Fabry Association (CFA) is committed to improving the lives of those who live with and are affected by Fabry disease in Canada.
Registration number 827560871RR0001
Connect with us